



UNITED STATES PATENT AND TRADEMARK OFFICE

JUN 17 2009

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
www.uspto.gov

Office of Regulatory Policy  
Food and Drug Administration  
10903 New Hampshire Ave., Bldg. 51, Rm. 6222  
Silver Spring, MD 20993-0002

Attention: Beverly Friedman

The attached documents relate to the patent term extension application for U.S. Patent No. 6,204,257, which was filed on February 6, 2009, under 35 U.S.C. § 156.

Applicant is fulfilling their duty of disclosure pursuant to 37 C.F.R. § 1.765 by submitting information to the USPTO and FDA indicating that more than one application for patent term extension was filed for the single regulatory review period for the human drug product, LUSEDRA™, NDA No. 02-2244.

Inquiries regarding this communication should be directed to the undersigned at (571) 272-7755 (telephone) or (571) 273-7755 (facsimile).

Mary C. Till  
Legal Advisor  
Office of Patent Legal Administration  
Office of the Deputy Commissioner  
for Patent Examination Policy

cc: Christopher N. Sipes  
Covington & Burling LLP  
1201 Pennsylvania Ave., NW  
Washington, DC 20004-2401